GenomaLab Medical Group has announced plans to invest nearly US$10 million during its first year of operations in the Sultanate of Oman. The healthcare and medical technology company is using its presence in SOHAR Port and Freezone as a base to serve Oman and potentially wider regional and international markets. The announcement signals growing private sector participation in advanced healthcare services under Oman Vision 2040.
Investment and Local Presence
The company has already started operations and is recruiting staff as it prepares to introduce a range of medical and biotechnology services. It expects to employ between 30 and 50 people during the initial phase, including at least 10 Omani nationals in line with local employment requirements. Dr. A Shavki, Chief Executive Officer of GenomaLab Medical LLC, confirmed the first year investment figure in an interview with the Oman Daily Observer.
GenomaLab plans to combine its Freezone operations with a mainland presence to strengthen access to hospitals, clinics, laboratories, research institutions, and patients. The Freezone site will support regional logistics and international activity, while the mainland operations will allow closer engagement across Oman's healthcare sector. This dual structure is intended to position the company for broader commercial and scientific reach.
Service Portfolio and Early Agreements
The company's initial focus includes continuous glucose monitoring systems and other diabetes technologies, home care products, cell and gene therapies, stem cell banking, and next generation sequencing, or NGS, tests. NGS technology enables the simultaneous analysis of large quantities of genetic material and can support the diagnosis and monitoring of inherited conditions, cancers, and other diseases. Rollout of these advanced services remains subject to local licensing and regulatory approvals.
GenomaLab has signed agreements with two clinics to provide services for diabetes patients, although the company did not disclose the names of the clinics or the commercial value of the agreements. It is also holding discussions with public and private sector organizations over stem cell biobanking, technology transfer, cell and gene therapy, and NGS testing services. Shavki said these partnerships are a key part of the company's early market entry.
The company plans to conduct a nationwide campaign in November offering free screening tests to diabetes patients. Further details about participating locations, clinics, and eligibility requirements are expected to be announced closer to the launch. Diabetes remains a major public health concern across the Gulf, increasing demand for early detection, continuous monitoring, and technologies that allow patients to manage their condition outside hospitals.
Strategic and Regulatory Context
Oman is seeking to attract more private sector participation in healthcare, expand local scientific capabilities, and increase the use of advanced medical technologies under Oman Vision 2040. GenomaLab said its Oman operation would combine local customer access with regional logistics and international scientific expertise. The company provides laboratory and healthcare infrastructure, diagnostic equipment, biotechnology services, cleanroom facilities, and related technical support.
Under its turnkey model, the group supports projects from initial planning and laboratory design to equipment installation, commissioning, validation, and the continuing supply of technologies and consumables. The proposed investment will be implemented as the company expands recruitment, develops partnerships, and introduces its services into the Omani market. GenomaLab has not disclosed whether the first year spending will include dedicated laboratory or production facilities, or provided a timetable for the full rollout of each service.
GenomaLab's planned US$10 million investment marks a significant step for advanced healthcare and biotechnology services in Oman. The company's early recruitment, clinic agreements, and planned screening campaign suggest a practical approach to building local demand and operational capacity. Its progress will depend on regulatory approvals, partnership development, and the successful integration of Freezone and mainland operations in the coming year.
Source: Observer